Torley Helen, President and CEO, has been actively engaged in insider trading activity involving shares of Halozyme Therapeutics, Inc. (HALO), as disclosed in SEC Form 4 filings. Over the course of 96 transactions, Helen has demonstrated a pronounced selling bias, with total sell transactions amounting to $33,914,013.51 compared to total buy transactions of $3,774,374.59. This significant disparity highlights a consistent trend of reducing her holdings in HALO. Notably, Helen has not made any recent purchases, with all seven of her latest transactions being sales or dispositions of shares.
Recent filings show a concentrated period of selling activity in early March 2026. On March 4, 2026, Helen sold shares worth $189,494.09 and $512,619.58, while also exercising market trades valued at $120,700. Earlier, on March 3, 2026, she sold shares totaling $451,981.83 and $928,166.85, alongside another market trade of $241,400. These transactions follow a pattern of substantial sales in late February 2026, including dispositions of $855,026.56 on February 23 and $641,659.20 on February 20. Additionally, on February 16, 2026, Helen executed multiple dispositions, including $2,192,941.20, $723,221.76, and $900,372.96, further underscoring her focus on reducing her stake in HALO.
Helen’s trading activity is exclusively tied to HALO, with no transactions involving other companies. The absence of recent purchases and the consistent selling pattern suggest a deliberate strategy to divest shares. This activity provides a clear snapshot of her financial moves within the company, reflecting a significant reduction in her equity position over time.
AI-assisted summary